Legion Partners Locks Up 17.3% Stake in Support of Webster Equity Merger
LFCR sits 83% above its 52-week low of $3.625 on elevated volume (19× avg).
Summary
Legion Partners, holding 17.3% of Lifecore, signed a voting agreement backing the Webster Equity Partners acquisition at $6.28 per share plus CVRs, locking up its shares and committing votes in favor of the deal.
Key Events · M&A and Partnerships · LFCR
-
Voting Agreement Signed
On September 27, 2026, Legion Partners entered a voting and support agreement, committing its 6,991,919 shares (17.3%) to vote in favor of the Webster Equity Partners merger and against any competing acquisition proposal.
-
Merger Consideration
Common stockholders receive $6.28 per share in cash plus one contingent value right (CVR) per share. Series A Preferred Stock converts to cash equal to its Conversion Amount plus CVRs.
-
Transfer Restrictions
Legion Partners agreed not to transfer any Covered Shares until the earlier of the stockholder vote, merger effective time, termination of the merger agreement, or a Company Adverse Change Recommendation.
-
Activist Alignment
Legion Partners had previously demanded redemption of its Series A Preferred Stock, creating liquidity pressure. The voting agreement removes this overhang and aligns the activist with the buyer.
Analysis · LFCR · Life Sciences
A binding voting agreement now commits activist investor Legion Partners to support the $6.28 per share cash-plus-CVR acquisition by Webster Equity Partners. The agreement bars Legion from transferring its 6.99 million shares and requires votes in favor of the merger and against any competing proposal. This removes a key obstacle to deal completion, as Legion had previously demanded redemption of its Series A Preferred Stock, creating liquidity pressure. The lock-up signals alignment between the activist and the buyer, increasing the probability the merger closes.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFCR was trading at $6.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $246.8M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.